Serum acute-phase proteins and immunoglobulins in patients with gliomas.
Cellular immune competence was found to be impaired in previous studies of patients with malignant brain tumors. In patients with nonneural tumors, we recently found that serum levels of acute-phase proteins were related to immune status as well as to tumor extent. To determine whether the serum proteins in patients with central nervous system tumors show similar changes, levels of acute-phase proteins (alpha1-acid glycoprotein, alpha1-antitrypsin, haptoglobin, C-reactive protein) and immunoglobulins (immunoglobulins G, M, and A) were assayed in patients with gliomas prior to treatment. Compared to normals, significant increases (p less than 0.001) in the acute-phase proteins were found, and the levels were similar to those in patients with nonneural solid neoplasms. Serum immunoglobulins were not significantly increased in patients with gliomas.
D000510:Alpha-Globulins / Q000032:analysis*; D001254:Astrocytoma / Q000097:blood / Q000276:immunology*; D001932:Brain Neoplasms / Q000097:blood / Q000276:immunology*; D005260:Female; D005909:Glioblastoma / Q000097:blood / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D007136:Immunoglobulins / Q000032:analysis*; D008297:Male; D009363:Neoplasm Proteins / Q000032:analysis
D000510:Alpha-Globulins; D007136:Immunoglobulins; D009363:Neoplasm Proteins